{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T07:49:56Z","timestamp":1775461796824,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug-induced gingival overgrowth (DIGO) is an increasingly relevant topic among dentists, physicians and patients as well. Due to high prescription rates of calcium channel blockers, anticonvulsants and immunosuppressants, the prevalence of this adverse effect should not be underestimated. In this paper, we compare the three groups of active substances mentioned and work out the drugs with the highest risk of triggering DIGO. Additionally, we compared package inserts (PIs) of the drugs in question to identify differences and missing references to this adverse drug reaction (ADR). It is a well-known problem that package inserts sometimes contain different information about adverse drug reactions and their frequencies. To find out what prevalence can actually be expected, we analysed various package inserts for different drugs that are known to cause DIGO. Moreover, we compared package inserts with summary of product characteristics (SmPCs) as an example. It turned out that both pieces of information shed light on the circumstances and problems of DIGO with roughly the same degree of imprecision and incompleteness. Furthermore, the given information in SmPCs are sometimes even worse than in the PIs. To find out the prevalence with which the various drugs potentially trigger DIGO, recent prescription figures must be taken into account. Using current data from the Arzneiverordnungsreport (drug prescription report, AVR) 2023 and the prevalences stated in PIs, we performed a model calculation of the expected number of patients in Germany developing DIGO per year. It turned out that substantial differences in the frequencies and the reported adverse drug reactions in the different package inserts can be found. Apart from this, the compared SmPC do not contain any further information on DIGO and its frequency. Surprisingly, long-term therapy with valproic acid is associated with the highest rate of DIGO compared to the other drugs. Despite the lower number of prescriptions, significantly more cases of DIGO must be expected with valproic acid therapy than with amlodipine or phenytoin, for example. To summarise, there are significant differences in the content of package inserts from different manufacturers. As a source of information for healthcare professionals, the SmPC unfortunately does not provide any detailed information on DIGO. In patients receiving long-term therapy with valproic acid, particular attention must be paid to the development of DIGO to initiate therapy at an early stage.<\/jats:p>","DOI":"10.1007\/s00210-025-04845-x","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:24:23Z","timestamp":1764224663000},"page":"6817-6831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Variations between package inserts regarding\u00a0gingival overgrowth causing drugs"],"prefix":"10.1007","volume":"399","author":[{"given":"Philipp Friedrich Georg","family":"Ried","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"4845_CR1","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2023.0153","author":"A Arning","year":"2023","unstructured":"Arning A, Seifert R (2023) Research letter. Dtsch Arztebl Int. https:\/\/doi.org\/10.3238\/arztebl.m2023.0153","journal-title":"Dtsch Arztebl Int"},{"key":"4845_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03430-y","author":"A Arning","year":"2024","unstructured":"Arning A, Seifert R (2024) Insufficient correctness of package inserts for psychotropic drugs in Germany. Naunyn-Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03430-y","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"15","key":"4845_CR3","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1212\/WNL.0b013e3182152844","volume":"76","author":"R Arya","year":"2011","unstructured":"Arya R, Gulati S, Kabra M, Sahu JK, Kalra V (2011) Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children. Neurology 76(15):1338\u20131343. https:\/\/doi.org\/10.1212\/WNL.0b013e3182152844","journal-title":"Neurology"},{"issue":"2","key":"4845_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.bdj.2017.71","volume":"222","author":"J Beaumont","year":"2017","unstructured":"Beaumont J, Chesterman J, Kellett M, Durey K (2017) Gingival overgrowth: Part 1: aetiology and clinical diagnosis. Br Dent J 222(2):85\u201391. https:\/\/doi.org\/10.1038\/sj.bdj.2017.71","journal-title":"Br Dent J"},{"issue":"5\u20136","key":"4845_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00228-005-0943-4","volume":"61","author":"V Bergk","year":"2005","unstructured":"Bergk V, Haefeli WE, Gasse C, Brenner H, Martin-Facklam M (2005) Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 61(5\u20136):327\u2013335. https:\/\/doi.org\/10.1007\/s00228-005-0943-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"4845_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4103\/0972-124X.113066","volume":"17","author":"V Bharti","year":"2013","unstructured":"Bharti V, Bansal C (2013) Drug-induced gingival overgrowth: the nemesis of gingiva unravelled. J Indian Soc Periodontol 17(2):182. https:\/\/doi.org\/10.4103\/0972-124X.113066","journal-title":"J Indian Soc Periodontol"},{"issue":"1","key":"4845_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/pds.795","volume":"12","author":"L Bjerrum","year":"2003","unstructured":"Bjerrum L, Foged A (2003) Patient information leaflets\u2013helpful guidance or a source of confusion? Pharmacoepidemiol Drug Saf 12(1):55\u201359. https:\/\/doi.org\/10.1002\/pds.795","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4845_CR8","unstructured":"Broich, K. (2015). Bekanntmachung von Empfehlungen zur Gestaltung von Packungsbeilagen nach \u00a7 11 des Arzneimittelgesetzes (AMG) f\u00fcr Humanarzneimittel (gem\u00e4\u00df \u00a7 77 Absatz 1 AMG) und zu den Anforderungen von \u00a7 22 Absatz 7 Satz 2 AMG (\u00dcberpr\u00fcfung der Verst\u00e4ndlichkeit von Packungsbeilagen). Accessed: 2025, 27.02 (https:\/\/www.bfarm.de\/SharedDocs\/Bekanntmachungen\/DE\/Arzneimittel\/natVerf\/bm-zul-20150414-packungsbeilagen_2015-pdf.pdf?__blob=publicationFile)"},{"key":"4845_CR9","doi-asserted-by":"publisher","unstructured":"Brown, R., & Arany, P. (2015). Mechanism of drug\u2010induced gingival overgrowth revisited: a unifying hypothesis. Oral Diseases, 21(1). https:\/\/doi.org\/10.1111\/odi.12264","DOI":"10.1111\/odi.12264"},{"key":"4845_CR10","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) (n.d.). Packungsbeilage. Accessed: 2025, 30.09 (https:\/\/www.bfarm.de\/DE\/Aktuelles\/Themendossiers\/Packungsbeilage\/_node.html)"},{"key":"4845_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15912","author":"J Chojnacka\u2010Purpurowicz","year":"2022","unstructured":"Chojnacka\u2010Purpurowicz J, Wygonowska E, Placek W, Owczarczyk\u2010Saczonek A (2022) Cyclosporine\u2010induced gingival overgrowth\u2014review. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.15912","journal-title":"Dermatol Ther"},{"issue":"10","key":"4845_CR12","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1902\/jop.2004.75.10.1424","volume":"75","author":"A Dongari-Bagtzoglou","year":"2004","unstructured":"Dongari-Bagtzoglou A (2004) Informational paper: drug\u2010associated gingival enlargement. J Periodontol 75(10):1424\u20131431. https:\/\/doi.org\/10.1902\/jop.2004.75.10.1424","journal-title":"J Periodontol"},{"issue":"6","key":"4845_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065448","volume":"24","author":"A Dro\u017adzik","year":"2023","unstructured":"Dro\u017adzik A, Dro\u017adzik M (2023) Drug-induced gingival overgrowth\u2014molecular aspects of drug actions. Int J Mol Sci 24(6):5448. https:\/\/doi.org\/10.3390\/ijms24065448","journal-title":"Int J Mol Sci"},{"key":"4845_CR14","unstructured":"European Union. (2025). RICHTLINIE 2001\/83\/EG DES EUROP\u00c4ISCHEN PARLAMENTS UND DES RATES. Accessed: 2025, 30.09 (https:\/\/eur-lex.europa.eu\/legal-content\/DE\/TXT\/HTML\/?uri=CELEX:02001L0083-20250101#tit_1)"},{"issue":"6","key":"4845_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.oooo.2019.07.022","volume":"128","author":"MD Fuchs","year":"2019","unstructured":"Fuchs MD, Signer-Buset SL, Mendes S, Schmidt JC, Walter C (2019) Does systemically administered azithromycin have an effect on gingival overgrowth? A systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol 128(6):606-614.e1. https:\/\/doi.org\/10.1016\/j.oooo.2019.07.022","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"3","key":"4845_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5144\/0256-4947.2006.192","volume":"26","author":"N Gebran","year":"2006","unstructured":"Gebran N, al Haidari K (2006) Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia. Ann Saudi Med 26(3):192\u2013199. https:\/\/doi.org\/10.5144\/0256-4947.2006.192","journal-title":"Ann Saudi Med"},{"issue":"2","key":"4845_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1034\/j.1600-051x.2000.027002109.x","volume":"27","author":"JA James","year":"2000","unstructured":"James JA, Marley JJ, Jamal S, Campbell BA, Short CD, Johnson RWG, Hull PS, Spratt H, Irwin CR, Boomer S, Maxwell AP, Linden GJ (2000) The calcium channel blocker used with cyclosporin has an effect on gingival overgrowth. J Clin Periodontol 27(2):109\u2013115. https:\/\/doi.org\/10.1034\/j.1600-051x.2000.027002109.x","journal-title":"J Clin Periodontol"},{"issue":"4","key":"4845_CR18","first-page":"236","volume":"69","author":"AH Khoori","year":"2003","unstructured":"Khoori AH, Einollahi B, Ansari G, Moozeh MB (2003) The effect of cyclosporine with and without nifedipine on gingival overgrowth in renal transplant patients. Journal (Canadian Dental Association) 69(4):236\u2013241 (PMID: 12662462)","journal-title":"Journal (Canadian Dental Association)"},{"issue":"10","key":"4845_CR19","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1080\/14740338.2021.1938539","volume":"20","author":"R Li","year":"2021","unstructured":"Li R, Curtis K, Zaidi STR, Van C, Thomson A, Castelino R (2021) Prevalence, characteristics, and reporting of adverse drug reactions in an Australian hospital: a retrospective review of hospital admissions due to adverse drug reactions. Expert Opin Drug Saf 20(10):1267\u20131274. https:\/\/doi.org\/10.1080\/14740338.2021.1938539","journal-title":"Expert Opin Drug Saf"},{"key":"4845_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-68371-2","volume-title":"Arzneiverordnungs-Report 2023","author":"W-D Ludwig","year":"2023","unstructured":"Ludwig W-D, M\u00fchlbauer B, Seifert R (2023) Arzneiverordnungs-Report 2023. Springer Berlin Heidelberg. https:\/\/doi.org\/10.1007\/978-3-662-68371-2"},{"issue":"5","key":"4845_CR21","first-page":"e10","volume":"61","author":"ML Moffitt","year":"2013","unstructured":"Moffitt ML, Cohen RE (2013) Non-drug induced gingival enlargement. Gen Dent 61(5):e10\u2013e13 (PMID: 23928447)","journal-title":"Gen Dent"},{"issue":"8","key":"4845_CR22","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1111\/epi.17299","volume":"63","author":"AJ Noble","year":"2022","unstructured":"Noble AJ, Haddad S, Coleman N, Marson AG (2022) Worth the paper they are printed on? Findings from an independent evaluation of the understandability of patient information leaflets for antiseizure medications. Epilepsia 63(8):2130\u20132143. https:\/\/doi.org\/10.1111\/epi.17299","journal-title":"Epilepsia"},{"key":"4845_CR23","doi-asserted-by":"publisher","unstructured":"Pont, L., Alhawassi, T., Bajorek, B., & Krass, I. (2014). A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clinical Interventions in Aging, 2079. https:\/\/doi.org\/10.2147\/CIA.S71178","DOI":"10.2147\/CIA.S71178"},{"issue":"4","key":"4845_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00228-003-0607-1","volume":"59","author":"V Reggi","year":"2003","unstructured":"Reggi V, Balocco-Mattavelli R, Bonati M, Breton I, Figueras A, Jambert E, Kopp C, Montane E, R\u00e4go L, Rocchi F (2003) Prescribing information in 26 countries: a comparative study. Eur J Clin Pharmacol 59(4):263\u2013270. https:\/\/doi.org\/10.1007\/s00228-003-0607-1","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"4845_CR25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.4045\/tidsskr.12.1272","volume":"133","author":"JG Storflor","year":"2013","unstructured":"Storflor JG, Pettersen LC, Sl\u00f8rdal L, Spigset O (2013) Legemidlers pakningsvedlegg \u2013 ulik informasjon om like preparater. Tidsskr Nor Laegeforen 133(9):955\u2013959. https:\/\/doi.org\/10.4045\/tidsskr.12.1272","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"1","key":"4845_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s007840050006","volume":"1","author":"JM Thomason","year":"1997","unstructured":"Thomason JM, Ellis JS, Kelly PJ, Seymour RA (1997) Nifedipine pharmacological variables as risk factors for gingival overgrowth in organ-transplant patients. Clin Oral Invest 1(1):35\u201339. https:\/\/doi.org\/10.1007\/s007840050006","journal-title":"Clin Oral Invest"},{"issue":"12","key":"4845_CR27","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1248\/yakushi.17-00164","volume":"137","author":"T Tomita","year":"2017","unstructured":"Tomita T (2017) Research on insufficient information for pharmaceutical products. Yakugaku Zasshi 137(12):1497\u20131504. https:\/\/doi.org\/10.1248\/yakushi.17-00164","journal-title":"Yakugaku Zasshi"},{"key":"4845_CR28","unstructured":"Tungare S, Paranjpe AG. Drug-induced gingival overgrowth. 2022 Sep 19. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. PMID: 30860753 Bookshelf ID: NBK538518"},{"issue":"5","key":"4845_CR29","first-page":"383","volume":"9","author":"S Vinker","year":"2007","unstructured":"Vinker S, Eliyahu V, Yaphe J (2007) The effect of drug information leaflets on patient behavior. The Israel Medical Association Journal\u202f: IMAJ 9(5):383\u2013386 (PMID: 17591379)","journal-title":"The Israel Medical Association Journal : IMAJ"},{"issue":"6","key":"4845_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1600-051X.1998.tb02474.x","volume":"25","author":"RF Wilson","year":"1998","unstructured":"Wilson RF, Morel A, Smith D, Koffman CG, Ogg CS, Rigden SPA, Ashley FP (1998) Contribution of individual drugs to gingival overgrowth in adult and juvenile renal transplant patients treated with multiple therapy. J Clin Periodontol 25(6):457\u2013464. https:\/\/doi.org\/10.1111\/j.1600-051X.1998.tb02474.x","journal-title":"J Clin Periodontol"},{"key":"4845_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211039099","author":"TM Yadesa","year":"2021","unstructured":"Yadesa TM, Kitutu FE, Deyno S, Ogwang PE, Tamukong R, Alele PE (2021) Prevalence, characteristics and predicting risk factors of adverse drug reactions among hospitalized older adults: a systematic review and meta-analysis. SAGE Open Med. https:\/\/doi.org\/10.1177\/20503121211039099","journal-title":"SAGE Open Med"},{"issue":"4","key":"4845_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1308\/205016820828463816","volume":"8","author":"N Zoheir","year":"2019","unstructured":"Zoheir N, Hughes FJ (2019) The management of drug-influenced gingival enlargement. Prim Dent J 8(4):34\u201339. https:\/\/doi.org\/10.1308\/205016820828463816","journal-title":"Prim Dent J"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04845-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04845-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04845-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:53:04Z","timestamp":1775458384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04845-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4845"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04845-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper has been published online prematurely. The authors have some additional correction in the body text. The incorrect version is now corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School (\n                      \n                      ) and officially registered as a doctoral thesis project for Philipp Friedrich Georg Ried. The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable because publicly available information is used as a data source.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.S. in the Editor-in-Chief of Naunyn-Schmiedebergs Arch Pharmacol and follows the editorial guidelines of editors acting as authors (\n                      \n                      ).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}